青少年及青年侵袭性B细胞非霍奇金淋巴瘤:儿童方案治疗结局更优
儿童中心患者的5年无事件生存率和总生存率均优于成人中心,校正组织学、分期和时期后差异仍显著。
要点
- 儿童中心治疗的AYA患者5年EFS和OS均显著优于成人中心。
- 校正组织学、分期和时期后,成人中心治疗的EFS和OS风险仍显著升高。
- 敏感性分析限于利妥昔单抗使用时期,差异仍存在。
核心结论
- 在青少年及青年侵袭性B细胞非霍奇金淋巴瘤中,儿童中心治疗与更优的EFS和OS相关,提示儿童方案可能带来获益。
主要发现
- 仅限多数成人中心患者接受利妥昔单抗的最近时期,敏感性分析显示类似差异。
临床怎么用
- 结果提示AYA侵袭性B-NHL患者接受儿童方案治疗可能改善生存,支持前瞻性研究验证。
局限性
- 为回顾性队列研究,作者指出需前瞻性研究验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Survival disparities by locus of care (LOC; paediatric versus adult) among adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) are well documented. Whether similar disparities exist among AYA with aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) is unknown. We identified all Ontario, Canada AYA aged 15-21 years at diagnosis of B-NHL between 1992 and 2012. Demographic, disease, treatment and outcome data were chart abstracted. The impact of LOC on event-free (EFS) and overall survival (OS) were determined, adjusted for patient and disease covariates. Among 176 AYA with B-NHL, 62 (35·2%) received therapy at paediatric centres. The 5-year EFS and OS [± standard error (SE)] for the overall cohort were 72·2 [3·4]% and 76·1 [3·2]% respectively. Both EFS and OS were superior among paediatric centre AYA [EFS (± SE) 82·2 (4·9)% vs. 66·7 (4·4)%, P = 0·02; OS 85·5 (4·5)% vs. 71·1 (4·3)%, P = 0·03]. Adjusted for histology, stage and time period, adult centre AYA had inferior EFS [hazard ratio (HR) 2·4, 95% confidence interval (CI) 1·1-4·9, P = 0·02] and OS (HR 2·5, 95% CI 1·1-5·7, P = 0·03). Sensitivity analyses restricted to the latest time period, when most adult centre AYA received rituximab, demonstrated similar disparities. Similar to AYA with ALL, AYA with B-NHL may benefit from being treated with paediatric protocols. Studies prospectively validating these results are warranted.
引用
- Gupta S, Alexander S, Pole JD, et al. Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2021. PMID: 34599525. doi:10.1111/bjh.17862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。